辉瑞/ BioNTech COVID-19疫苗的真实世界证据

2021-03-15 Allan MedSci原创

近日,以色列卫生部(MoH)收集的真实世界证据表明,辉瑞/ BioNTech的COVID-19疫苗“大大”降低了完全接种疫苗的个体中COVID-19的发生率。

辉瑞公司与以色列卫生部在1月份签署了一项合作协议,以监测辉瑞/ BioNTech疫苗在真实世界中的影响。近日,以色列卫生部(MoH)收集的真实世界证据表明,辉瑞/ BioNTech的COVID-19疫苗“大大”降低了完全接种疫苗的个体中COVID-19的发生率。

以色列卫生部的最新分析发现,第二剂疫苗接种两周后,保护作用更强。辉瑞/ BioNTech的COVID-19疫苗在预防症状性疾病、严重疾病和死亡的有效性至少为97%。分析的结果来自于2021年1月17日至3月6日收集的总体监测数据,当时辉瑞/ BioNTech疫苗是以色列唯一可用的疫苗。

分析还发现,针对无症状SARS-CoV-2感染的有效性为94%。

辉瑞疫苗高级副总裁兼首席医疗官Luis Jodar说:“我们非常高兴的是,来自以色列的真实世界数据证实了我们在III期临床试验中显示出的高功效,并显示了该疫苗在预防COVID-19引起的严重疾病和死亡方面的重大影响。这项发现表明该疫苗还可以保护人们免受无症状SARS-CoV-2感染的侵害”。

 

原始出处:

http://www.pharmatimes.com/news/new_real-world_evidence_for_pfizerbiontech_covid-19_vaccine_1365128

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652466, encodeId=880b16524663e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu May 06 22:19:20 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919224, encodeId=d4aa1919224ca, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 26 18:19:20 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=424, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93725, encryptionId=952e93e2512, topicName=辉瑞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:10:01 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295293, encodeId=dad81295293f5, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948659, encodeId=0d6b948659c3, content=赞梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Tue Mar 16 12:55:19 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
    2021-05-06 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652466, encodeId=880b16524663e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu May 06 22:19:20 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919224, encodeId=d4aa1919224ca, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 26 18:19:20 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=424, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93725, encryptionId=952e93e2512, topicName=辉瑞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:10:01 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295293, encodeId=dad81295293f5, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948659, encodeId=0d6b948659c3, content=赞梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Tue Mar 16 12:55:19 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
    2021-03-26 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652466, encodeId=880b16524663e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu May 06 22:19:20 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919224, encodeId=d4aa1919224ca, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 26 18:19:20 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=424, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93725, encryptionId=952e93e2512, topicName=辉瑞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:10:01 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295293, encodeId=dad81295293f5, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948659, encodeId=0d6b948659c3, content=赞梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Tue Mar 16 12:55:19 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652466, encodeId=880b16524663e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu May 06 22:19:20 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919224, encodeId=d4aa1919224ca, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 26 18:19:20 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=424, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93725, encryptionId=952e93e2512, topicName=辉瑞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:10:01 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295293, encodeId=dad81295293f5, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948659, encodeId=0d6b948659c3, content=赞梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Tue Mar 16 12:55:19 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1652466, encodeId=880b16524663e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu May 06 22:19:20 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919224, encodeId=d4aa1919224ca, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 26 18:19:20 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=424, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93725, encryptionId=952e93e2512, topicName=辉瑞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:10:01 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295293, encodeId=dad81295293f5, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948659, encodeId=0d6b948659c3, content=赞梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Tue Mar 16 12:55:19 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1652466, encodeId=880b16524663e, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Thu May 06 22:19:20 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919224, encodeId=d4aa1919224ca, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Mar 26 18:19:20 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004058, encodeId=017a100405818, content=<a href='/topic/show?id=952e93e2512' target=_blank style='color:#2F92EE;'>#辉瑞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=424, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93725, encryptionId=952e93e2512, topicName=辉瑞)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:10:01 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295293, encodeId=dad81295293f5, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1391181, encodeId=29a61391181ef, content=<a href='/topic/show?id=9c5e34585a' target=_blank style='color:#2F92EE;'>#BioNTech#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3458, encryptionId=9c5e34585a, topicName=BioNTech)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e3fb2500073, createdName=124987cdm26暂无昵称, createdTime=Wed Mar 17 11:19:20 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948659, encodeId=0d6b948659c3, content=赞梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210127/50a003c4097845e182c08afd64d8a509/bd766dfebe9c40e0bca2dae964601bdc.jpg, createdBy=22de5454917, createdName=carrotlyl, createdTime=Tue Mar 16 12:55:19 CST 2021, time=2021-03-16, status=1, ipAttribution=)]
    2021-03-16 carrotlyl

    赞梅斯

    0

相关资讯

J Autoimmun:风湿病患者是否更易感COVID-19?

自身免疫性风湿病(ARD)患者是否具有较高的SARS-CoV-2感染风险(COVID-19),以及SARS-CoV-2大流行对治疗依从性的影响尚未完全阐明。近日,来自意大利的研究人员调查了本地一所三级

JAMA:COVID-19 Ad26.COV2.S疫苗在人类试验中的免疫原性研究

Ad26.COV2.S能诱导快速而复杂的抗体反应以及细胞免疫反应。

J INTERN MED:COVID-19患者动脉僵硬度及其与临床结局的潜在关联

COVID-19似乎与PWV升高有关,表明这类患者动脉僵硬度有所增加。较高的PWV可能与住院时间延长和死亡率增加有关。

JAMA:证据来了,伊维菌素不适用于治疗新冠肺炎!

曾获诺奖药物伊维菌素并不适用于治疗治疗轻度COVID-19。

重症COVID-19患者的死亡率降低24%!Leronlimab显功效

生物技术公司CytoDyn正在开发Vyrologix™(leronlimab-PRO 140),这是一种具有多种治疗适应症的CCR5拮抗剂。

Nature:COVID疫情对科研人员的影响

资助者和负责评估政策的人必须重新设定对研究进行估值、衡量和评估的方式。但是,最终需要从根本上解决不平等问题,消除差异,这样研究人员就不会处于劣势。

拓展阅读

JAMA Netw Open:COVID-19大流行对儿童呼吸道病原体检测率的影响

儿童呼吸道病原体检测率在COVID-19大流行期间显著上升且持续高位,急诊组检测率增幅尤为突出。

Pediatrics:COVID-19大流行期间儿童胆囊切除术增加

本研究表明,COVID-19大流行期间,儿童胆囊切除术案例数量和复杂性均有所增加。这些发现可能与儿童健康状况的变化、转诊模式以及就医途径的转变有关,这突显了儿童医院日益增加的医疗保健负担。

Arthritis Care Res:农村地区居住的特发性免疫性或炎症性风湿病患者在COVID-19感染后的两年内死亡风险如何?

农村地区居住的特发性免疫性或炎症性风湿病患者在COVID-19感染后的两年内死亡风险较高。

Epidemiology and Psychiatric Sciences:疫情期间青少年和年轻人抗抑郁药物使用激增的时间序列分析洞察

COVID-19疫情期间,青少年和年轻人抗抑郁药物使用显著增加,特别是女性和非意大利籍青少年增幅尤为突出,提示心理健康需求可能在疫情后持续增加。

Int Forum Allergy Rhinol:嗅觉训练与年龄有关的差异

美国科学家发现,50岁以下的年轻患者和50岁以上的年长患者在接受OT治疗后,嗅觉功能都有类似的明显改善。但两组患者的主观改善时间不同,年轻患者的改善时间更早。

如何设定重症患者和手术室中的初始呼吸频率?对使用机械通气的 COVID-19 患者的初始设置的影响。

讨论机械通气患者呼吸频率设置,不同患者情况不同,重症患者常需较高呼吸频率,对 COVID-19 患者也给出相应设置建议。